Aravive, Inc. – NASDAQ:ARAV
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 7 hours
Aravive stock price monthly change
-68.82%
month
Aravive stock price quarterly change
-70.80%
quarter
Aravive stock price yearly change
-97.66%
year
Aravive key metrics
Market Cap | 2.94M |
Enterprise value | 14.76M |
P/E | -0.84 |
EV/Sales | 1.24 |
EV/EBITDA | -0.13 |
Price/Sales | 5.43 |
Price/Book | 6.04 |
PEG ratio | 0.10 |
EPS | -1.17 |
Revenue | 6.99M |
EBITDA | -84.23M |
Income | -81.15M |
Revenue Q/Q | -44.39% |
Revenue Y/Y | -19.11% |
Profit margin | -910.64% |
Oper. margin | -888.74% |
Gross margin | 0% |
EBIT margin | -888.74% |
EBITDA margin | -1204.2% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAravive stock price history
Aravive stock forecast
Aravive financial statements
| Dec 2022 | 1.47M | -38.38M | -2604.14% |
|---|---|---|---|
| Mar 2023 | 1.49M | -81.99M | -5499.6% |
| Jun 2023 | 1.27M | 18.00M | 1413.5% |
| Sep 2023 | 2.75M | 21.22M | 770.17% |
| 2025 | 1.46M | -24M | -1636.36% |
|---|
Analysts Price target
Financials & Ratios estimates
| Dec 2022 | 62153000 | 51.49M | 82.85% |
|---|---|---|---|
| Mar 2023 | 43044000 | 81.65M | 189.7% |
| Jun 2023 | 25737000 | 45.55M | 177% |
| Sep 2023 | 13049000 | 11.34M | 86.96% |
| Dec 2022 | -14.23M | -11K | 40.04M |
|---|---|---|---|
| Mar 2023 | -17.75M | 0 | 0 |
| Jun 2023 | -17.65M | 0 | 25K |
| Sep 2023 | -9.80M | 0 | 25K |
Aravive alternative data
| Aug 2023 | 23 |
|---|---|
| Sep 2023 | 23 |
| Oct 2023 | 23 |
| Nov 2023 | 23 |
| Dec 2023 | 23 |
| Jan 2024 | 23 |
| Feb 2024 | 23 |
| Mar 2024 | 23 |
| Apr 2024 | 23 |
| May 2024 | 23 |
| Jun 2024 | 23 |
| Jul 2024 | 23 |
Aravive other data
100.00%
0.00%
of ARAV is owned by hedge funds
16
-14
6.29M
-8.91M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2020 | 16000 | 0 |
| Jun 2021 | 2000 | 0 |
| Nov 2021 | 0 | 3245 |
| Insider | Compensation |
|---|---|
Dr. Gail F. McIntyre CH (ASCP), DABT, Ph.D. (1963) Pres, Chief Executive Officer & Director | $562,470 |
Mr. Vinay Shah MBA (1963) Chief Financial Officer | $481,990 |
| Dr. Reshma Rangwala M.D., Ph.D. (1978) Chief Medical Officer | $455,810 |
-
When is Aravive's next earnings date?
Unfortunately, Aravive's (ARAV) next earnings date is currently unknown.
-
Does Aravive pay dividends?
No, Aravive does not pay dividends.
-
How much money does Aravive make?
Aravive has a market capitalization of 2.94M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 22.78% to 9.14M US dollars.
-
What is Aravive's stock symbol?
Aravive, Inc. is traded on the NASDAQ under the ticker symbol "ARAV".
-
What is Aravive's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Aravive?
Shares of Aravive can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Aravive's key executives?
Aravive's management team includes the following people:
- Dr. Gail F. McIntyre CH (ASCP), DABT, Ph.D. Pres, Chief Executive Officer & Director(age: 62, pay: $562,470)
- Mr. Vinay Shah MBA Chief Financial Officer(age: 62, pay: $481,990)
- Dr. Reshma Rangwala M.D., Ph.D. Chief Medical Officer(age: 47, pay: $455,810)
-
How many employees does Aravive have?
As Jul 2024, Aravive employs 23 workers.
-
When Aravive went public?
Aravive, Inc. is publicly traded company for more then 11 years since IPO on 21 Mar 2014.
-
What is Aravive's official website?
The official website for Aravive is aravive.com.
-
Where are Aravive's headquarters?
Aravive is headquartered at River Oaks Tower, Houston, TX.
-
How can i contact Aravive?
Aravive's mailing address is River Oaks Tower, Houston, TX and company can be reached via phone at +93 63551910.
Aravive company profile:
Aravive, Inc.
aravive.comExchange:
NASDAQ
Full time employees:
23
Industry:
Biotechnology
Sector:
Healthcare
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.
River Oaks Tower
Houston, TX 77098
Houston, TX 77098
CIK: 0001513818
ISIN: US03890D1081
CUSIP: 03890D108
